Pharmabiz1d
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
Boehringer Ingelheim and Synaffix B.V. (Synaffix), a Lonza company focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs ...
Pharmabiz1d
Gaelic Labs establishes subsidiary in UAE, enabling access to growing Middle East pharma market
Gaelic Laboratories, a European CMO based in Ireland, has established a subsidiary in the UAE, enabling access to the Middle East market – both for Gaelic Laboratories and its marketing partners ...
Pharmabiz1d
Seven research leaders awarded prestigious NIHR award
The NIHR has announced the latest outstanding researchers to become NIHR Research Professors. They will play a key role in undertaking professorial-level research that has a positive impact on the ...
Pharmabiz1d
US FDA grants priority review status to Johnson & Johnson’s nipocalimab BLA to treat generalized myasthenia gravis
Johnson & Johnson announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the US Food and Drug Administration (FDA) for the treatment of antibody ...
Pharmabiz1d
EU looks at India as best option over China, reflecting potential shifts in trade dynamics
The European Union's preference for India over China in the pharmaceutical sector is rooted in several strategic factors including the access to qualified and skilled workforce. India has a proven ...
Pharmabiz1d
Astellas Pharma announces US FDA confirms Class 1 resubmission of the sNDA for Izervay for geographic atrophy
Astellas Pharma Inc. announced the US Food and Drug Administration (FDA) accepted the revised supplemental New Drug Application (sNDA) for Izervay (avacincaptad pegol intravitreal solution) for the ...
Pharmabiz1d
US FDA accepts for review GSK’s Shingrix new prefilled syringe presentation
GSK plc, a global biopharma company, announced that the US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s ...
Pharmabiz1d
Dr D Ramanathan wins Dhanwanthari Award for his contributions to Ayurveda
Dr D Ramanathan, managing director of Sitaram Ayurveda Pharmacy, Thrissur and general secretary of the Ayurveda Medicine Manufacturers Organisation of India (AMMOI), has won the prestigious ...
Pharmabiz1d
IDMA plans extensive workshops on revised Schedule M to assist pharma MSMEs
With revision in extension of the deadline for implementing the revised Schedule M until December 31, 2025, the Indian Drug Manufacturers’ Association (IDMA) has announced plans to intensify its ...
Pharmabiz2d
Novo Nordisk and Valo Health expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Novo Nordisk A/S, a leading global healthcare company, and Valo Health, Inc. announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 ...
Pharmabiz1d
SMPMA urges govt to drop conditions mandated for extension of revised Schedule M implementation
The Delhi-based Small and Medium Pharma Manufacturers Association (SMPMA) has urged the Union health ministry to drop the conditions mandated in the draft notification for extension of compliance with ...
Pharmabiz1d
NPPA recalculates ceiling price of azithromycin 250 mg following review order
The National Pharmaceutical Pricing Authority (NPPA) has released the revised calculation sheet for the ceiling price of azithromycin 250 mg tablet following a review order from the Department of ...